4D Molecular Therapeutics (FDMT) Price & Analysis

Compare

515 Followers

FDMT Stock Chart & Stats

$9.66

-$0.14(-2.20%)

At close: Jan 08 4:00 PM EST

$9.66

-$0.14(-2.20%)

Day’s Range― - ―

52-Week Range$2.24 - $12.34

Previous CloseN/A

Volume165.32K

Average Volume (3M)736.92K

Market Cap

$492.74M

Enterprise Value$466.44M

Total Cash (Recent Filing)$305.06M

Total Debt (Recent Filing)$22.26M

Price to Earnings (P/E)―

Beta0.82

Next Earnings

May 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding51,007,874

10 Day Avg. Volume751,996

30 Day Avg. Volume736,921

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)0.59

Price to Sales (P/S)8120.72

P/FCF Ratio-2.17

Enterprise Value/Market Cap0.95

Enterprise Value/Revenue3.89K

Enterprise Value/Gross Profit-4.82

Enterprise Value/Ebitda-2.06

Forecast

1Y Price Target

$36.25

Price Target Upside275.26% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-3.48

Revenue Forecast (FY)$19.01M

Bulls Say, Bears Say

Bulls Say

Clinical DataInterim Phase 1 data showed physiologically relevant CFTR expression and early signs of lung function improvement for 4D-710, supporting continued clinical development.

Dose SelectionSelection of the 2.5E14 vg dose met the target expression profile and was confirmed as the anticipated pivotal and commercial dose, streamlining the Phase 2 development plan.

Market Opportunity And FundingTargeting patients intolerant or ineligible for CFTR modulators addresses a clear unmet need and CF Foundation funding supports advancement toward Phase 2 evaluation.

Bears Say

Development Complexity And CostNeed to re-optimize dosing to avoid expression in undesirable cell types could require additional studies, increasing development complexity and program costs.

Dose-limiting EfficacyOff-target expression observed at higher doses may force a conservative dose ceiling, which could limit therapeutic benefit for patients who require higher levels of CFTR expression.

Safety And Regulatory RiskHigher doses produced transgene expression above target levels and in undesirable cell types, creating potential safety concerns that could complicate regulatory review.

4D Molecular Therapeutics News

4D Molecular completes enrollment for 4FRONT-1 Phase 3 trial

4D Molecular (FDMT) Therapeutics announced enrollment completion for 4FRONT-1, the first Phase 3 clinical trial evaluating 4D-150 in...

21d ago

FDMT

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings Cheat Sheet

4D Molecular Therapeutics, Inc. (FDMT) is scheduled to report 4th quarter earnings on 02/27/2026. Regarding Q4 estimates, Wall...

5d ago

FDMT

4D Molecular assumed with an Overweight at Barclays

Barclays assumed coverage of 4D Molecular (FDMT) with an Overweight rating and $33 price target Barclays initiated coverage...

1M ago

FDMT

4D Molecular Therapeutics Restructures Equity via Warrant Exchange

An announcement from 4D Molecular Therapeutics ( ($FDMT) ) is now available. On January 22, 2026, 4D Molecular...

1M ago

FDMT

4D Molecular announces employment inducement grants

4D Molecular (FDMT) Therapeutics announced that on January 13, 2026, the compensation committee of the Company’s board of...

1M ago

FDMT

4D Molecular Therapeutics Expands Leadership With New Director Appointment

An announcement from 4D Molecular Therapeutics ( ($FDMT) ) is now available. On December 31, 2025, Fariborz Kamal,...

2M ago

FDMT

4D Molecular Therapeutics: Encouraging Early CF Gene Therapy Signals Tempered by Limited Data, Supporting a Neutral Hold Rating

Morgan Stanley analyst Judah Frommer has maintained their neutral stance on FDMT stock, giving a Hold rating on...

2M ago

FDMT

4D Molecular announces interim data from 4D-710 Phase 1 AEROW trial

4D Molecular (FDMT) Therapeutics announced positive interim clinical data from the 4D-710 Phase 1 AEROW clinical trial for...

3M ago

FDMT

4D Molecular Therapeutics Expands Phase 3 Trial Enrollment

4D Molecular Therapeutics ( ($FDMT) ) has shared an update. On December 10, 2025, 4D Molecular Therapeutics announced...

3M ago

FDMT

4D Molecular Therapeutics Appoints New Chief Financial Officer

4D Molecular Therapeutics ( ($FDMT) ) just unveiled an update. On November 17, 2025, 4D Molecular Therapeutics, Inc....

4M ago

FDMT

4D Molecular names Kristian Humer as CFO

4D Molecular (FDMT) Therapeutics announced the appointment of Kristian Humer as CFO. Humer will lead the company’s financial...

4M ago

FDMT

Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position

4D Molecular Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield...

4M ago

FDMT

4D Molecular price target raised to $32 from $26 at RBC Capital

RBC Capital analyst Lisa Walter raised the firm’s price target on 4D Molecular (FDMT) to $32 from $26...

4M ago

FDMT

4D Molecular price target lowered to $33 from $38 at Barclays

Barclays analyst Gena Wang lowered the firm’s price target on 4D Molecular (FDMT) to $33 from $38 and...

4M ago

FDMT

FDMT FAQ

What was 4D Molecular Therapeutics’s price range in the past 12 months?

4D Molecular Therapeutics lowest stock price was $2.23 and its highest was $12.34 in the past 12 months.

What is 4D Molecular Therapeutics’s market cap?

4D Molecular Therapeutics’s market cap is $492.74M.

When is 4D Molecular Therapeutics’s upcoming earnings report date?

4D Molecular Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 66 days.

How were 4D Molecular Therapeutics’s earnings last quarter?

Currently, no data Available

Is 4D Molecular Therapeutics overvalued?

According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does 4D Molecular Therapeutics pay dividends?

4D Molecular Therapeutics does not currently pay dividends.

What is 4D Molecular Therapeutics’s EPS estimate?

4D Molecular Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does 4D Molecular Therapeutics have?

4D Molecular Therapeutics has 51,007,874 shares outstanding.

What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of 4D Molecular Therapeutics?

Currently, no hedge funds are holding shares in FDMT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

4D Molecular Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-45.38%

Trailing 12-Months

Asset Growth

-29.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

4D Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics (FDMT) Earnings & Revenues

Historic Earnings Reports

FDMT Stock 12 Month Forecast

Average Price Target

$36.25

▲(275.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","46":"$46","12.25":"$12.25","23.5":"$23.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,12.25,23.5,34.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,11.907692307692308,14.665384615384616,17.423076923076923,20.18076923076923,22.93846153846154,25.696153846153848,28.45384615384615,31.21153846153846,33.96923076923077,36.72692307692308,39.48461538461538,42.24230769230769,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,11.234615384615385,13.31923076923077,15.403846153846155,17.48846153846154,19.573076923076925,21.657692307692308,23.742307692307694,25.82692307692308,27.911538461538463,29.996153846153845,32.080769230769235,34.16538461538462,{"y":36.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,10.830769230769231,12.511538461538462,14.192307692307693,15.873076923076923,17.553846153846152,19.234615384615385,20.915384615384617,22.596153846153847,24.276923076923076,25.957692307692305,27.63846153846154,29.31923076923077,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >